Monitor for future updates on product launch timelines and any revenue recognition from the IBT partnership; this could signal successful commercial execution, which is critical for a company with a history of net losses.
Price Chart
Executive Summary
Dyadic International has entered into an OEM distribution agreement with IBT Bioservices to commercialize Dyadic's recombinant protein products, including DNase I and transferrin, through IBT's global sales channels. This marks a strategic shift toward product-based revenue and expands market access without requiring Dyadic to build its own commercial infrastructure.
Key Facts
- Dyadic entered an OEM distribution deal with IBT Bioservices to sell recombinant proteins like DNase I and transferrin.
- Products will be marketed for research-use-only (RUO) applications globally via IBT’s established distribution network.
- Initial focus includes human and bovine transferrin, with potential expansion to other cell culture-relevant proteins.
- Agreement supports Dyadic’s transition from R&D-driven to commercial product-based revenue streams.
- No financial terms (e.g., deal value, revenue projections) were disclosed.
Financial Impact
Potential for incremental revenue growth over time; no specific figures disclosed
Risk Factors
- No guaranteed revenue — success depends on market adoption and IBT's sales performance.
- Dyadic remains pre-revenue at scale, with continued reliance on partnerships and external funding.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3256153 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | SC 13G | $0.4194 | awaiting T+20 | — | $0.4050 (−3.43%) |
Sep 25, 2026 4w ago | 8-K | $0.4650 $0.4160 | ▲ +10.54% | ▲ +10.51% | $0.4050 (+12.90%) |
Sep 21, 2026 5w ago | EFFECT | $0.4010 $0.3809 | ▲ +5.01% | ▲ +4.10% | $0.4050 (−1.00%) |
Aug 14, 2026 10w ago | 8-K | $0.7751 $0.4244 | ▲ +45.25% | ▲ +43.25% | $0.4050 (+47.75%) |
Aug 12, 2026 10w ago | 8-K | $0.8800 $0.4898 | ▲ +44.34% | ▲ +42.44% | $0.4050 (+53.98%) |
Aug 12, 2026 10w ago | Press Release | $0.8800 $0.4898 | ▲ +44.34% | ▲ +42.44% | $0.4050 (+53.98%) |
Jul 24, 2026 13w ago | 8-K | $1.19 $0.6900 | ▼ −42.02% | ▼ −45.64% | $0.4050 (−65.97%) |
Jun 18, 2026 18w ago | DEFA14A | $0.7820 $1.19 | ▼ −52.17% | ▼ −51.64% | $0.4050 (+48.21%) |
May 28, 2026 21w ago | 8-K | $0.7100 $0.8010 | ▲ +12.82% | ▲ +15.96% | $0.4050 (−42.96%) |
Mar 25, 2026 30w ago | Press Release | $0.7000 $0.8600 | ▲ +22.86% | ▲ +12.19% | $0.4050 (−42.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers